Glaukos (GKOS) Stock Price, News & Analysis

Company Overview

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions. Its iDose TR implant delivers a controlled release of travoprost directly into the eye over several months, aiming to reduce patient compliance issues associated with daily eye drops. Through its acquisition of Avedro in 2019, Glaukos also offers corneal cross-linking technologies and other phototherapeutic solutions for the treatment of keratoconus and corneal ectasia, broadening the company’s presence in the ophthalmic market.

Founded in 1998 and headquartered in San Clemente, California, Glaukos has built a global commercial organization serving surgeons and patients in North America, Europe, Asia Pacific and the Middle East. The company combines direct sales teams in key markets with strategic distribution partnerships to support product training, clinical research and market access. Glaukos continuously invests in research and development to advance its pipeline of minimally invasive ophthalmic therapies.

Leadership at Glaukos is headed by President and Chief Executive Officer Thomas Burns, who joined the company in 2018 and has overseen its expansion into new therapeutic areas and geographies. Under his guidance, Glaukos remains committed to improving patient outcomes through novel, less-invasive treatments that aim to preserve vision and enhance quality of life for individuals living with glaucoma and other eye diseases.

Key Stats

• Today's Range: $74.55 to $76.08
• 50-Day Range: $74.60 to $96.54
• 52-Week Range: $73.73 to $163.71
• Volume: 1.31 million shs
• Average Volume: 1.04 million shs
• Market Capitalization: $4.28 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $116.92
• Consensus Rating: Moderate Buy

Glaukos Stock Analysis - MarketRank™

Glaukos scored higher than 90% of companies evaluated by MarketBeat, and ranked 91st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Glaukos has a consensus price target of $116.92, representing about 56.7% upside from its current price of $74.60.

Amount of Analyst Coverage

Glaukos has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Glaukos is -45.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Glaukos is -45.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Glaukos has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.49% of the outstanding shares of Glaukos have been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Glaukos has recently decreased by 2.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Glaukos does not currently pay a dividend.

Dividend Growth

Glaukos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

5.49% of the outstanding shares of Glaukos have been sold short.

Short Interest Ratio / Days to Cover

Glaukos has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Glaukos has recently decreased by 2.48%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.56

News Sentiment

Glaukos has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Glaukos this week, compared to 8 articles on an average week.

Search Interest

21 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

8 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Glaukos insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.80% of the stock of Glaukos is held by insiders.

Percentage Held by Institutions

99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GKOS Stock Analysis - Frequently Asked Questions

How have GKOS shares performed this year?

Glaukos' stock was trading at $149.94 on January 1st, 2025. Since then, GKOS stock has decreased by 50.2% and is now trading at $74.6020.

How were Glaukos' earnings last quarter?

Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings data on Wednesday, July, 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. The company's quarterly revenue was up 29.7% compared to the same quarter last year.
Read the conference call transcript.

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Top institutional investors of Glaukos include Riverbridge Partners LLC (0.99%), Allspring Global Investments Holdings LLC (0.47%), Assenagon Asset Management S.A. (0.27%) and Voya Investment Management LLC (0.22%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 10/25/2025
• Next Earnings (Confirmed): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:GKOS
• CIK: 1192448
• Web: www.glaukos.com
• Phone: (949) 367-9600
• Fax: 949-367-9984
• Employees: 780
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Glaukos: $116.92
• High Price Target: $165.00
• Low Price Target: $72.00
• Potential Upside/Downside: +56.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.37 million
• Net Margins: -21.43%
• Pretax Margin: -21.28%
• Return on Equity: -8.59%
• Return on Assets: -6.61%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 5.51
• Quick Ratio: 4.69

Sales & Book Value

• Annual Sales: $383.48 million
• Price / Sales: 11.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.91 per share
• Price / Book: 5.36

Miscellaneous

• Outstanding Shares: 57,350,000
• Free Float: 54,024,000
• Market Cap: $4.28 billion
• Optionable: Optionable
• Beta: 0.76